



BSW Formulary Updates and Recent Decisions – November 2024

New additions to BSWformulary and Change in Traffic Light Status (TLS)

- [Loperamide Orodispersible](#) – Added with a **RED** TLS as an option for oncology teams to use in people with oesophageal cancer where opening capsules or crushing standard tablets has not been successful.
- [Primidone tablets](#) – Added as **AMBER** for essential tremor to allow GPs to prescribe following specialist initiation or recommendation.
- [Risankizumab](#) and [Etrasimod](#) – Included as options in the updated [BSW Inflammatory Bowel Disease Pathway](#) for treatment of ulcerative colitis as per NICE TA998 and TA956 respectively.
- [Linzagolix Tablets](#) – Added as **AMBER** in line with NICE TA996. New local guidance published here: [Linzagolix \(Yselyt\) for treatment of uterine fibroids](#)

New and Updated Prescribing Guidelines and Shared Care Agreements

- **UPDATE - [BSW Malnutrition screening tools](#)** - This **MUST** pathway combines the previous two documents. It links into prescribing and gives guidance for starting, reviewing and stopping.
- **UPDATE - [BSW Oral Nutrition Supplements adult formulary](#)** – Dietetic support varies across BSW, this pathway guides prescribers to be able to prescribe for patients at risk, or suggest they purchase OTC, first line products to try before referring to dieticians.

Minor amendments to Netformulary

- Wording amended to [Penthrox®](#) entry
- [Victoza](#) brand of liraglutide has been discontinued and removed from formulary.
- [Shingrix®](#) vaccine programme had been updated.
- Clarification that [aspirin enteric coated](#) are non-formulary.

What the BSW ICB formulary team are currently working on

- Review currently underway of the migraine pathway.
- Smoking cessation pathway and the reintroduction of varenicline being updated.
- Reviewing position of daily Tadalafil 5mg.
- Review of abaloparatide for treating osteoporosis after menopause as per [NICE TA991](#)
- Formulary position of faricimab being reviewed for treating visual impairment caused by macular oedema after retinal vein occlusion as per [NICE TA1004](#)

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net